Press Release – Santa Monica, CA and Salt Lake City, UT, May 23, 2017 (PRBUZZ) — Leonhardt’s Launchpads announces today that the Company has filed a provisional patent application to expand its current intellectual property portfolio to now include a harmonic vibrational resonance energy device to prevent blood clots, plaque and calcification on blood contact surfaces such as circulatory assist pumps and heart valves. The new patent application will strengthen the Company’s overall patent coverage related in organ regeneration and recovery technologies and will allow the Company to address a growing market segment of cardiovascular devices and biological treatments.
Abstract: Harmonic vibrational device for preventing thrombosis formation on blood contact devices. Device first non-invasively scans the blood contact device or natural blood contact vessel and determines the highest risk thrombosis points. The device then, starting with the highest risk location, delivers a succession of harmonic vibration signals non-invasively until harmonic resonance is reached for each stagnation high risk point of the blood contact device. This resonant vibration calibration tuning information is stored in the microprocessor. The signals are then delivered, based on the stored information, in a loop from the signal generator, usually on a belt outside the patient, to each stagnation point in sequence from highest risk of thrombosis to lowest again and again repeated. By delivering harmonic resonant vibrational energy to the blood contact device stagnation points the beginning of thrombosis formation is prevented thus preventing the accumulation of thrombosis to a dangerous risk level for stroke, pulmonary embolism or other blood clot induced ailments. This device may be used to prevent blood clot, plaque and calcification formation on any blood contact surfaces including living surfaces such as heart valves. Inventors: Howard J. Leonhardt & Jeff Donofrio
“The Company continues to stay true to its mission and looks forward to being able to share its new organ regeneration and recovery designs with current and potential future strategic partners organ by organ. Thrombosis, plaque and calcification formation are the achilles heel of many implantable cardiovascular devices and are a major problem within the natural vessels of the human body. We are striving to develop products that reduce these associated risks for patients in need. Step by step we continue to build our intellectual property estate for organ regeneration and recovery technologies and today is another big step in that direction. “ stated Howard J. Leonhardt, Co-Inventor, Executive Chairman and CEO of Leonhardt’s Launchpads by Cal-X Stars Business Accelerator, Inc. and Leonhardt Ventures.
A recent New England Journal of Medicine Article – Unexpected Abrupt Increase in Left Ventricular Assist Device Thrombosis – published this analysis of thrombosis within left ventricular assist devices “A total of 72 confirmed pump thromboses were observed in 66 patients, and an additional 36 thromboses in unique devices were suspected. The risk of confirmed pump thrombosis peaked at 1.4% per month within 1 month after implantation.” Click here for full article – http://www.nejm.org/doi/full/10.1056/NEJMoa1313385#t=article
The company also announced today the following licensing agreements with the below listed entities* with terms undisclosed for the vibrational energy device technology the subject of today’s provisional patent filing:
Second Heart Assist, Inc. – temporary and chronic aortic positioned circulatory assist devices – http://leonhardtventures.com/second-heart/
Valvublator – heart valve decalcification and regeneration – http://valvublator.com/
EndoCell – artery regeneration – http://leonhardtventures.com/endocell/
MyoStim Peripheral – limb salvage, diabetic foot and leg ulcer treatment and critical limb ischemia.
CerebraCell – brain regeneration, concussion + stroke recovery, Alzheimer’s and Parkinson’s treatment – http://leonhardtventures.com/cerebracell/
Leonhardt announced earlier this year signed patent option agreements with the California Institute of Technology (Caltech) and Neuro Code Tech Holdings LLC for over a half dozen issued patents for circulatory assist and bioelectric driven organ recovery (see links below). The company has filed its own full patent applications in recent months for bioelectric organ regeneration and bioelectric driven accelerated tooth movement with the help of the intellectual property law firm Trask & Britt of Salt Lake City, Utah. Howard Leonhardt previously patented a vibrational energy device for increasing gas exchange for intravascular lung devices – https://www.google.com/patents/US5788668 that was a constant vibration delivered via coiled guide wire without tuning to resonant frequencies at stagnation points.
About Leonhardt’s Launchpads: Leonhardt’s Launchpads by Cal-X Stars Business Accelerator, Inc. operates innovation incubators/accelerators focused primarily on organ regeneration and recovery in California and Utah. Locations in California include Santa Monica (headquarters) and Santa Rosa in collaboration with the University of Northern California Science & Technology Innovation Center (UNC STIC). In 2015 Leonhardt’s Launchpads Utah, Inc. was formed and formally incorporated in 2016. 30 startups are currently incubating/accelerating within the firm’s three locations. The company conducts research at its own space at the BioInnovations Gateway lab in Utah as well as through collaborations with a number of Universities. Leonhardt’s Launchpads has signed aboard more than 80 experienced business mentors http://calxstars.com/team-cal-x/ and 35 scientific advisory board http://calxstars.com/scientific-advisory-board/ members. Web sites: www.calxstars.com and http://leonhardtventures.com/leonhardts-launchpads-utah/
About Leonhardt Ventures: Leonhardt Ventures was formed in 1982 as HJ Leonhardt & Co. and became an LLC in 2005 (Leonhardt Vineyards LLC DBA Leonhardt Ventures). This LLC is the holding company for founder Howard J. Leonhardt’s inventions and share holdings in various startups in the Regenerative Medtech, Regenerative Economy and Food & Beverage sectors of specialization. Leonhardt developed in the 1980’s a series of patented cardiovascular balloon catheters, in the 1990’s stent grafts and percutaneous heart valves and since 1999 has specialized primarily in bioelectric, micro pump and stem cell composition driven organ regeneration and recovery technologies. Leonhardt Vineyards LLC began growing grapes and making plus marketing wine in 2000 in Sonoma County, CA. Web Sites: http://leonhardtvineyards.com/our-story/ + www.leonhardtventures.com
Caution Regarding Forward-Looking Statements: This news release contains certain forward-looking statements by Leonhardt’s Launchpads by Cal-X Stars Business Accelerator, Inc. that involve risks and uncertainties and reflect the company’s judgment as of the date of this release. These statements include those referring to the patent application, uses, market opportunities, and goals for bringing to marketbrand new un-tested inventions. Actual events or results may differ from Leonhardt’s Launchpads expectations. There can be no assurance that the U.S. Patent and Trademark Office will grant the patent in a timely manner or at all, that the FDA will approve the product for market, that over-the-counter sales will be permitted, or if permitted that there will be market acceptance of the product at any meaningful level. Additional information concerning these and other risk factors affecting Leonhardt’s Launchpads business can be found in the company’s web sites, annual reports and newsletters. The company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Leonhardt’s Launchpads works with a small staff and limited budget managing the acceleration of 30+ startups and has many thousands of web site updates a year. Our over 40 web sites may contain outdated data as a result. If you have any specific questions please email us direct to firstname.lastname@example.org
* Note – The listed entities are all startups within the Leonhardt’s Launchpads innovation accelerators. Those not yet incorporated are organized into organ specific Licensable Technology Platforms (LTP’s) until they are mature enough to be incorporated and stand on their own .
Provisional patent application mentioned above was filed via LegalZoomTM software.
Cautionary Statement: Safety and efficacy of this newly developed device is not yet proven in pre-clinical or clinical studies.
Leonhardt’s Launchpads by Cal-X Stars Business Accelerator, Inc., 2000 Main Street, Unit 333, Santa Monica, CA 90405 – www.leonhardtventures.com + www.calxstars.com
Leonhardt’s Launchpads Utah, Inc. 370 S, 300 E, Salt Lake City, UT 84111
Research Lab @ 2500 S State St. #224, Salt Lake City, UT 84115
Central Google Voice Mail # for All Startups: (424) 291-2133
Previous Related Press Releases:
Leonhardt Announces Patent Option License Bioelectric Cancer Treatment http://leonhardtventures.com/leonhardt-ventures-enter-worldwide-strategic-collaboration-neuro-code-tech-holdings-customized-bioelectric-cancer-treatments/
Leonhardt Announces Patent Option License Agreement with Caltech for Circulatory Assist Technologies http://leonhardtventures.com/leonhardts-launchpads-expands-patent-estate-option-exclusive-license-agreement-caltech/
Leonhardt Files Provisional Patent Application for Heart Valve Decalcification and Regeneration http://www.biospace.com/News/leonhardt-ventures-files-patent-for-heart-valve/426286
Leonhardt and Genvose File Provisional Patent Application for Controlled PDGF Release for Organ Regeneration – http://www.biospace.com/News/leonhardt-and-genovese-file-patent-for-bioelectric/442460